Anixa is a biotechnology company developing a number of programs addressing cancer and infectious disease. 

Anixa's therapeutics portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therapeutics program focused on inhibiting certain viral protein function. 

Anixa’s diagnostics portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. 

Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

Strong Leadership Backed by Success

Our management team has had many successes, especially in connection with starting, building and investing in technology related companies.

View Management Team

View Board of Directors